4 transcripts
VKTX
Earnings call transcript
NASDAQ
2024 Q2
24 Jul 24
of treatment. We also announced the initial results from a Phase I trial evaluating a novel oral formulation of VK2735 in healthy volunteers, which showed
VKTX
Earnings call transcript
NASDAQ
2024 Q1
24 Apr 24
an oral tablet formulation of VK2735 in healthy volunteers. Both studies were successful, demonstrating promising weight loss and favorable safety
VKTX
Earnings call transcript
NASDAQ
2023 Q4
7 Feb 24
levels of apolipoprotein B were also reduced by up to 21%. These data are particularly interesting in light of the fact that these healthy volunteers
VKTX
Earnings call transcript
NASDAQ
2023 Q2
26 Jul 23
in healthy volunteers who have a minimum body mass index of 30 kilograms per meter squared. Subjects will receive daily oral doses for 28 days. The primary
- Prev
- 1
- Next